Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 68 | 2024 | 760 | 12.130 |
Why?
|
| Hypoglycemic Agents | 45 | 2024 | 184 | 9.250 |
Why?
|
| Insulin | 24 | 2024 | 258 | 7.950 |
Why?
|
| Diabetes Mellitus | 38 | 2024 | 539 | 7.000 |
Why?
|
| Blood Glucose | 36 | 2024 | 389 | 5.240 |
Why?
|
| Prediabetic State | 10 | 2023 | 69 | 5.000 |
Why?
|
| Thiazolidinediones | 10 | 2020 | 49 | 3.140 |
Why?
|
| Blood Glucose Self-Monitoring | 10 | 2024 | 33 | 3.030 |
Why?
|
| Algorithms | 12 | 2024 | 509 | 2.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2024 | 92 | 2.290 |
Why?
|
| Cardiovascular Diseases | 8 | 2023 | 749 | 2.150 |
Why?
|
| Primary Health Care | 6 | 2024 | 380 | 2.030 |
Why?
|
| Metformin | 6 | 2020 | 75 | 1.880 |
Why?
|
| Humans | 117 | 2024 | 43102 | 1.800 |
Why?
|
| Glucose Tolerance Test | 10 | 2012 | 75 | 1.460 |
Why?
|
| Life Style | 6 | 2023 | 334 | 1.440 |
Why?
|
| Glucose Intolerance | 5 | 2023 | 40 | 1.300 |
Why?
|
| Insulin Resistance | 5 | 2013 | 201 | 1.170 |
Why?
|
| Hyperglycemia | 6 | 2022 | 61 | 1.150 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 235 | 1.110 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 78 | 1.100 |
Why?
|
| Societies, Medical | 10 | 2014 | 74 | 1.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 89 | 0.950 |
Why?
|
| Research Support as Topic | 5 | 2004 | 89 | 0.950 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2024 | 3 | 0.900 |
Why?
|
| Vitamin D | 3 | 2021 | 196 | 0.810 |
Why?
|
| Fasting | 9 | 2020 | 56 | 0.810 |
Why?
|
| Middle Aged | 29 | 2024 | 12222 | 0.810 |
Why?
|
| Diabetes Complications | 3 | 2009 | 102 | 0.790 |
Why?
|
| Quality of Life | 5 | 2014 | 616 | 0.790 |
Why?
|
| Male | 36 | 2024 | 23409 | 0.780 |
Why?
|
| Adult | 22 | 2023 | 13872 | 0.750 |
Why?
|
| Insulin Infusion Systems | 2 | 2024 | 8 | 0.730 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 375 | 0.720 |
Why?
|
| Female | 34 | 2024 | 24698 | 0.690 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 17 | 0.670 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 5 | 0.640 |
Why?
|
| Minority Groups | 4 | 2007 | 690 | 0.620 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 19 | 0.620 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 44 | 0.610 |
Why?
|
| Risk Factors | 11 | 2023 | 3994 | 0.580 |
Why?
|
| Self Care | 6 | 2017 | 175 | 0.570 |
Why?
|
| Albuminuria | 2 | 2011 | 78 | 0.550 |
Why?
|
| Aged | 16 | 2019 | 8214 | 0.550 |
Why?
|
| Clinical Protocols | 1 | 2017 | 36 | 0.540 |
Why?
|
| Cholesterol, LDL | 5 | 2017 | 73 | 0.510 |
Why?
|
| Cost-Benefit Analysis | 6 | 2020 | 179 | 0.490 |
Why?
|
| United States | 20 | 2014 | 5205 | 0.490 |
Why?
|
| Obesity | 4 | 2022 | 1151 | 0.490 |
Why?
|
| Weight Loss | 3 | 2023 | 137 | 0.470 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 234 | 0.460 |
Why?
|
| Reproducibility of Results | 11 | 2010 | 1081 | 0.460 |
Why?
|
| Reminder Systems | 2 | 2005 | 16 | 0.440 |
Why?
|
| Health Transition | 1 | 2014 | 4 | 0.430 |
Why?
|
| Sertraline | 2 | 2011 | 7 | 0.430 |
Why?
|
| Outsourced Services | 2 | 2004 | 5 | 0.410 |
Why?
|
| Disease Management | 3 | 2014 | 70 | 0.410 |
Why?
|
| Dyslipidemias | 1 | 2014 | 48 | 0.410 |
Why?
|
| Antidepressive Agents | 2 | 2011 | 65 | 0.410 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 56 | 0.410 |
Why?
|
| Delivery of Health Care | 3 | 2009 | 310 | 0.400 |
Why?
|
| Glucose Clamp Technique | 1 | 2013 | 7 | 0.390 |
Why?
|
| Nursing Care | 2 | 2010 | 7 | 0.390 |
Why?
|
| Blood Pressure | 6 | 2017 | 666 | 0.380 |
Why?
|
| Research Design | 1 | 2014 | 385 | 0.360 |
Why?
|
| Pyrazines | 1 | 2011 | 32 | 0.350 |
Why?
|
| Pharmacists | 2 | 2009 | 61 | 0.340 |
Why?
|
| Postprandial Period | 1 | 2010 | 13 | 0.330 |
Why?
|
| Triazoles | 1 | 2011 | 102 | 0.330 |
Why?
|
| Hypertension | 2 | 2014 | 835 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 40 | 0.320 |
Why?
|
| Treatment Outcome | 7 | 2011 | 1604 | 0.310 |
Why?
|
| Injections | 3 | 2019 | 42 | 0.310 |
Why?
|
| Breath Tests | 1 | 2009 | 24 | 0.310 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 34 | 0.300 |
Why?
|
| Prevalence | 5 | 2017 | 1612 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2011 | 187 | 0.300 |
Why?
|
| Drug Administration Schedule | 4 | 2014 | 153 | 0.300 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1067 | 0.300 |
Why?
|
| Needles | 1 | 2008 | 10 | 0.290 |
Why?
|
| Cohort Studies | 3 | 2019 | 1759 | 0.290 |
Why?
|
| Hospitalization | 3 | 2008 | 485 | 0.280 |
Why?
|
| Cholecalciferol | 2 | 2021 | 20 | 0.280 |
Why?
|
| Thyrotropin | 1 | 2008 | 24 | 0.280 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 26 | 0.270 |
Why?
|
| Glyburide | 1 | 2007 | 9 | 0.270 |
Why?
|
| Managed Care Programs | 1 | 2007 | 40 | 0.250 |
Why?
|
| Insulin, Long-Acting | 2 | 2020 | 3 | 0.250 |
Why?
|
| Islam | 1 | 2006 | 17 | 0.240 |
Why?
|
| Treatment Failure | 2 | 2019 | 60 | 0.240 |
Why?
|
| Venoms | 1 | 2005 | 18 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1124 | 0.230 |
Why?
|
| Drug Costs | 2 | 2020 | 35 | 0.230 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 5 | 0.230 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 10 | 0.220 |
Why?
|
| Reagent Strips | 1 | 2004 | 3 | 0.220 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 60 | 0.210 |
Why?
|
| Double-Blind Method | 3 | 2012 | 317 | 0.210 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2004 | 11 | 0.210 |
Why?
|
| Community Health Centers | 2 | 2005 | 57 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2023 | 925 | 0.210 |
Why?
|
| Medication Adherence | 2 | 2017 | 182 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2004 | 75 | 0.210 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 43 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 17 | 0.210 |
Why?
|
| Peer Review, Research | 1 | 2003 | 15 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.200 |
Why?
|
| Specialties, Nursing | 1 | 2003 | 1 | 0.200 |
Why?
|
| Inpatients | 1 | 2004 | 78 | 0.200 |
Why?
|
| Enalapril | 1 | 2002 | 7 | 0.190 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 3 | 0.190 |
Why?
|
| Vitamins | 2 | 2021 | 81 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 78 | 0.190 |
Why?
|
| Depression | 1 | 2009 | 863 | 0.180 |
Why?
|
| Peptides | 1 | 2005 | 372 | 0.180 |
Why?
|
| Glucose | 2 | 2017 | 244 | 0.180 |
Why?
|
| Canada | 1 | 2022 | 163 | 0.180 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 52 | 0.170 |
Why?
|
| Risk | 2 | 2017 | 287 | 0.170 |
Why?
|
| Young Adult | 4 | 2014 | 5080 | 0.170 |
Why?
|
| Europe | 4 | 2014 | 115 | 0.160 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Time Factors | 2 | 2019 | 1857 | 0.160 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 263 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 223 | 0.150 |
Why?
|
| Pregnancy | 2 | 2020 | 1772 | 0.150 |
Why?
|
| Family Characteristics | 1 | 2020 | 126 | 0.150 |
Why?
|
| Antimalarials | 1 | 2019 | 64 | 0.150 |
Why?
|
| Sex Factors | 2 | 2014 | 1028 | 0.140 |
Why?
|
| Community Health Services | 2 | 2014 | 206 | 0.140 |
Why?
|
| Disease Progression | 1 | 2020 | 667 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 36 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 2853 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 760 | 0.130 |
Why?
|
| Mass Screening | 2 | 2014 | 541 | 0.120 |
Why?
|
| Prognosis | 1 | 2019 | 861 | 0.120 |
Why?
|
| Drug Industry | 1 | 2016 | 18 | 0.120 |
Why?
|
| Los Angeles | 4 | 2005 | 394 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 121 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 55 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2019 | 1600 | 0.110 |
Why?
|
| California | 2 | 2007 | 548 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2014 | 213 | 0.110 |
Why?
|
| Overweight | 1 | 2016 | 249 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2014 | 38 | 0.110 |
Why?
|
| Tissue Distribution | 1 | 2014 | 240 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2014 | 90 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 165 | 0.100 |
Why?
|
| Lipids | 1 | 2014 | 256 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2014 | 180 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 442 | 0.080 |
Why?
|
| C-Peptide | 1 | 2009 | 7 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.080 |
Why?
|
| Adolescent | 2 | 2011 | 6081 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 41 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2007 | 2544 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 19 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 28 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2009 | 86 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 611 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 99 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2010 | 490 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2010 | 246 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 440 | 0.070 |
Why?
|
| Health Surveys | 1 | 2010 | 405 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 78 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 260 | 0.070 |
Why?
|
| Homeostasis | 2 | 2014 | 192 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2011 | 549 | 0.070 |
Why?
|
| Body Weight | 1 | 2009 | 429 | 0.070 |
Why?
|
| Nurses | 1 | 2007 | 55 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 159 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1154 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2006 | 18 | 0.060 |
Why?
|
| Lung | 1 | 2009 | 492 | 0.060 |
Why?
|
| Angina, Unstable | 1 | 2005 | 9 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 34 | 0.060 |
Why?
|
| Focus Groups | 2 | 2005 | 423 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 10 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 29 | 0.060 |
Why?
|
| Weight Gain | 1 | 2006 | 139 | 0.060 |
Why?
|
| Marketing | 1 | 2005 | 45 | 0.060 |
Why?
|
| Arizona | 1 | 2005 | 139 | 0.060 |
Why?
|
| Triglycerides | 1 | 2005 | 147 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 120 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2009 | 638 | 0.050 |
Why?
|
| Age of Onset | 1 | 2004 | 114 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 233 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 54 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2004 | 185 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 211 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2003 | 98 | 0.050 |
Why?
|
| Length of Stay | 1 | 2004 | 229 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 247 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 59 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 125 | 0.050 |
Why?
|
| Proteinuria | 1 | 2002 | 56 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 123 | 0.050 |
Why?
|
| Medicare | 1 | 2005 | 332 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 89 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 339 | 0.050 |
Why?
|
| Heart Failure | 1 | 2005 | 302 | 0.050 |
Why?
|
| Anxiety | 1 | 2009 | 874 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 238 | 0.040 |
Why?
|
| Apoptosis | 1 | 2009 | 1568 | 0.040 |
Why?
|
| Urban Population | 1 | 2003 | 374 | 0.040 |
Why?
|
| Communication | 1 | 2003 | 210 | 0.040 |
Why?
|
| Patient Selection | 1 | 2002 | 205 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2005 | 11 | 0.010 |
Why?
|
| Pravastatin | 1 | 2003 | 6 | 0.010 |
Why?
|
| Lovastatin | 1 | 2003 | 9 | 0.010 |
Why?
|
| Child | 1 | 2012 | 3443 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2003 | 20 | 0.010 |
Why?
|
| Simvastatin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Pyrroles | 1 | 2003 | 72 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2005 | 219 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 277 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 187 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 989 | 0.010 |
Why?
|